Opinion|Videos|November 7, 2024
Treatment Considerations for Disease Progression
With Eileen O’Reilly, MD, the Oncology Brothers discuss treatment considerations for disease progression in pancreatic cancer, focusing on the management of refractory disease, shifting therapeutic strategies, and optimizing patient care in advanced stages.
Advertisement
Advertisement
Related to this article
Ursula A. Matulonis, MD, discussed how biomarkers, adverse effects, and patient preference guide choices among recent platinum-resistant ovarian cancer approvals.
Alexandra Dreyfuss, MD, MS, explains why CAR T and bispecific populations are her priority for prospective radiotherapy studies in multiple myeloma.
Dr. Andrew Pecora on leading the first IV oncolytic virus trial, building a top-50 cancer center, and using AI to fix the cost of cancer care.
Ralph V. Boccia, MD, FACP, explained how community practices can build the workflow and capacity to deliver bispecific step-up dosing in an outpatient setting.
There is a gap in prospective data for radiation use in multiple myeloma, according to Alexandra Dreyfuss, MD, MS.
Erik Bengtsen, MD, explained how antidepressants may improve quality of life and how he typically works with patients who decline favorable treatment.
Nikolai Strusberg, MD, discussed how proton therapy and thyroid dose affect clinical hypothyroidism risk after supraclavicular breast radiation.
Ralph V. Boccia, MD, FACP, compared MRD data with Tec-Dara and Tal-Dara and explained how sustained MRD negativity is reshaping myeloma care.
Advertisement
Advertisement
Trending on CancerNetwork
1
VS-7375 Yields Responses in KRAS G12D–Mutated Solid Tumors
2
Reading a Changed Eye Examination and Impact on Therapy
3
Personalized Cancer Vaccine Combo Is Feasible in Platinum-Sensitive Ovarian Cancer
4
ASH Issues New Myelofibrosis Guidelines With 10 Management Recommendations
5